Rallybio Corp. (RLYB) - Forward P/S Multiple

Brandmark of Rallybio Corp. (RLYB)

The forward P/S multiple dynamics for Rallybio Corporation (RLYB) correlate with clinical trial success and acquisition prospects. Meanwhile, 194.30 represents the current value of this metric. Asset value growth is driven by the development of unique therapies for rare fetal pathologies. Process stability is maintained through scheduled laboratory operations and the reconfiguration of external contractor capacities for the production of pilot batches.

RLYB Rallybio Corp: Price-to-Projected Revenue Ratio in the range 08/10/2024 - 11/15/2026

RLYB (Rallybio): analytical breakdowns and indicator data

- market price and analyst price targets:
- market capitalization indicators:
Summary company analytics:Rallybio Corp RLYB
Manufactured products of rallybio.com

Forward P/S compares current market capitalization with projected revenue, reflecting market expectations for future cash flows and the level of confidence in management guidance. For Rallybio Corporation (RLYB), where business value depends on the complexity of the cold chain supply for orphan drugs, the expected P/S metric on GURU.Markets demonstrates how investors assess the efficiency of the logistics infrastructure and the commercialization potential of the portfolio.

Analysis of competing companies

Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|Verona Pharma PLC - Forward P/S Multiple|Market Cap to Future Revenue Ratio jyongbio.com|LGND: Forward P/S Multiple|Market Cap to Projected Revenue AMRX|Price-to-Projected Revenue Ratio Perrigo Company|Market Cap to Future Revenue Ratio Alvotech ALVO|Forward P/S Multiple LQDA|GLPG: Future Price to Revenue|Forward P/S Multiple ANIP (ANI Pharmaceuticals, Inc.)|Market Cap to Expected Sales Ratio MannKind Corp (MNKD)|AMPH: Forward Price-to-Revenue Multiple|Forward Price to Sales PCRX (Pacira)|ARS Pharmaceuticals (SPRY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TBPH|AQST (Aquestive Corp) - Forward P/S Multiple|Forward Price-to-Revenue Multiple scPharmaceuticals Inc. (SCPH)|Forward Price-to-Revenue Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharmaceuticals Holding) - Forward Price to Sales|Price-to-Projected Revenue Ratio SXT Pharmaceuticals SXTC|Forward Price to Sales EPRX|BHST - Price-to-Projected Revenue Ratio|eXoZymes (EXOZ) - Forward Price-to-Revenue Multiple|ORMP: Forward P/S Multiple|ENTX: Price to Expected Revenue Ratio|HYFT (ipatherapeutics.com) - Forward P/S Multiple|Forward P/S Multiple ABVC BioPharma|Price-to-Projected Revenue Ratio Cumberland Pharmaceuticals Inc. (CPIX)|QNTM (Quantum BioPharma Ltd.) - Forward Price to Sales|Forward P/S Multiple FGEN (fibrogen.com)|Telomir Pharmaceuticals (TELO) - Market Cap to Future Revenue Ratio|RANI - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Synergy CHC SNYR|LEXX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pulmatrix Inc|PTHL (Pheton Holdings) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aptorum Group Limited APM|Price-to-Projected Revenue Ratio Lyra Therapeutics (LYRA)|Forward Price-to-Revenue Multiple Impact BioMedical Inc IBO|Price-to-Projected Revenue Ratio tnfpharma.com TNFA|Forward Price to Sales YCBD|PainReform Ltd - Forward P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Forward Price-to-Revenue Multiple|lipella.com (LIPO) - Price-to-Projected Revenue Ratio|OptiNose (OPTN) - Forward P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP